Irene Becklund Sells 4,490 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 4,490 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $141,435.00. Following the completion of the sale, the insider directly owned 6,790 shares of the company’s stock, valued at $213,885. This trade represents a 39.80% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Irene Becklund also recently made the following trade(s):

• On Tuesday, June 16th, Irene Becklund sold 7,573 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.25, for a total transaction of $229,083.25.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $35.44 on Friday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The stock has a market cap of $8.20 billion, a PE ratio of -393.79, a PEG ratio of 45.59 and a beta of 2.37. The company’s fifty day moving average is $26.42 and its 200 day moving average is $26.58. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the business posted $0.20 earnings per share. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.05 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $28,000. Silicon Valley Capital Partners bought a new position in shares of Hims & Hers Health during the third quarter valued at approximately $48,000. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $28,000. Bogart Wealth LLC raised its holdings in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after acquiring an additional 283 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on HIMS shares. UBS Group set a $23.00 price target on Hims & Hers Health in a research note on Friday, May 22nd. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a report on Tuesday, May 12th. Zacks Research cut shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, June 8th. Canaccord Genuity Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Finally, Morgan Stanley lowered their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $29.37.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Barclays raised its price target on Hims & Hers and maintained a bullish stance, reinforcing optimism around accelerating growth and margin improvement tied to the Novo Nordisk partnership. Hims & Hers Stock Jumps After Barclays Raises Price Target
• Positive Sentiment: Analysts and commentators see the company as a potential beneficiary of the peptide/GLP-1 market and an upcoming FDA review, which may provide a new catalyst for future growth. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
• Positive Sentiment: Bullish coverage argues that international expansion and the renewed partnership with Novo Nordisk support Hims & Hers’ long-term revenue and EBITDA targets. Hims & Hers: The Bull Case Remains Strong
• Neutral Sentiment: Insider selling by Irene Becklund and COO Michael Chi was disclosed, but both transactions were tied to pre-arranged 10b5-1 plans and equity-award tax withholding, which makes the signal less concerning for investors. SEC filing for Michael Chi sale
• Negative Sentiment: Recent commentary still points to weak prior-quarter fundamentals, including modest revenue growth, declining margins, and a net loss, reminding investors that execution risk remains. Hims & Hers: The Bull Case Remains Strong

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.